ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The Russell 2000 Growth Index increased by 25.6% in the second quarter, marking its third-best quarterly performance in two decades. The rally was fueled by enthusiasm for AI, strength in biotech, and gains in high-beta, high-momentum stocks, amid rising retail trading activity and narrow leadership in specific themes. Despite a complex macroeconomic backdrop and ongoing debates about the pace and impact of AI infrastructure investments, enthusiasm for generational technology investments remains robust. The Strategy achieved strong absolute returns of over 21% (gross) during the quarter but lagged the Russell 2000 Growth benchmark due to underperformance in certain healthcare and financial stocks, software challenges, and limited exposure to high-beta, high-momentum AI-related stocks. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Clearbridge Small Cap Growth Strategy highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases. On July 23, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $107.41 per share, reflecting a market capitalization of $23.28 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month return of 3.06%, and its shares gained 2.50% over the past 52 weeks.
Clearbridge Small Cap Growth Strategy stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor update:
“In health care, weakness was concentrated in a few idiosyncratic holdings, despite a strong quarter for biotech. Long-standing biotech holding Insmed Incorporated (NASDAQ:INSM) gave up some of the prior year’s strength driven by concerns around the pace of key drug Brinsupri’s launch. We remain confident in the meaningful long-term peak sales potential and believe recent weakness has been overly punitive.”
Insmed Incorporated (NASDAQ:INSM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 67 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the first quarter, compared to 75 in the previous quarter. While we acknowledge the risk and potential of Insmed Incorporated (NASDAQ:INSM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Insmed Incorporated (NASDAQ:INSM) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Insmed Incorporated (NASDAQ:INSM) and shared Alger Mid Cap Focus Fund’s views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
